XNAS · Healthcare · Biotechnology
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.20 | -0.16 | +20.00% | $2.7M | ✅ Beat | -0.95% | -3.42% | — |
| 2026-03-17 | Q4 2025 | -0.35 | -0.22 | +37.14% | $2.6M | ✅ Beat | +3.93% | -9.69% | -2.13% |
| 2025-11-05 |
| Q3 2025 |
| -0.82 |
| -0.69 |
| +15.85% |
| $1.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -1.86 | -3.47 | -86.56% | $2.0M | ❌ Miss | +0.00% | +91.28% | +127.52% |
| 2025-05-01 | Q1 2025 | -3.75 | 0.04 | +101.07% | $28.8M | ✅ Beat | -0.67% | -12.27% | +1.60% |
| 2025-03-25 | Q4 2024 | -0.16 | -0.20 | -25.00% | $1.4M | ❌ Miss | +3.86% | -14.53% | -27.83% |
| 2024-11-13 | Q3 2024 | -0.17 | -0.18 | -5.88% | $560,000 | ❌ Miss | +47.85% | +22.76% | +141.69% |
| 2024-05-07 | Q1 2024 | -0.16 | -0.26 | -62.50% | $0 | ❌ Miss | -4.59% | -9.60% | -6.42% |
Showing last 8 quarters.